US FDA Authorizes Lilly’s COVID-19 mAB Combo For Lower Doses Than Tested In Phase III

 
• By Sue Sutter
Small car
Lilly's BLAZE-1 trial showed that large mAB doses are effective, but the FDA believes lower doses will have a similar clinical effect. • Source: Shutterstock

More from Approvals

More from Product Reviews